Guangzhou Unveils 15th Five-Year Marine Economy Plan, Backs AI-Driven Marine Drugs

The notable shift here is structural: Guangzhou is treating marine bioprospecting as a data and platform play, pairing a gene bank with an AI development model rather than funding isolated drug programmes. That matters for the broader RWA and biotech-data conversation, because a curated repository of South China Sea drug-source organisms becomes the kind of proprietary dataset that underpins licensing and asset tokenisation later. The near-term focus on commodity-adjacent outputs — fish oil, collagen, chitosan, algal polysaccharides — suggests a lower-risk revenue base first. Whether the gene bank is opened to external researchers is the open question.